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The subcutaneous Matrigel plug assay in mice is a method of choice for the in 
vivo evaluation of pro- and anti-angiogenic molecules. However, quantification of the 
angiogenic response in the plug remains a problematic task. Here we report a sim-
ple, rapid, unbiased and reverse transcription-quantitative PCR (RT-qPCR) method to 
investigate the angiogenic process occurring in the Matrigel plug in response to fibro-
blast growth factor-2 (FGF2).
To this purpose, a fixed amount of human cells were added to harvested plugs 
at the end of the in vivo experimentation as an external cell tracer. Then, mRNA lev-
els of the pan endothelial cell markers murine CD31 and vascular endothelial-cadherin 
were measured by species-specific RT-qPCR analysis of the total RNA and data were 
normalized for human GAPDH or β-actin mRNA levels. RT-qPCR was used also to 
measure the levels of expression in the plug of various angiogenesis/inflammation-
related genes. The procedure allows the simultaneous, quantitative evaluation of the 
newly-formed endothelium and of non endothelial/inflammatory components of the 
cellular infiltrate in the Matrigel implant, as well as the expression of genes involved 
in the modulation of the angiogenesis process. Also, the method consents the quanti-
tative assessment of the effect of local or systemic administration of anti-angiogenic 
compounds on the neovascular response triggered by FGF2.
